The European Commission has approved Merck's (NYSE: MRK) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a perioperative treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA